

Online Supplement

Original Research

Navigating COPD and Bronchiectasis: A COPD Foundation 360 Social Survey of Health Care Experiences and Perceptions

Radmila Choate, PhD, MPH¹ Timothy R. Aksamit, MD² John Torrence, TTS³ Phyliss A. DiLorenzo, BA³ Arturo Rodriguez, PhD³ Bruce Miller, PhD³ Jean Wright, MD, MBA³ Dawn L. DeMeo, MD, MPH⁴


¹Department of Epidemiology and Environmental Health, College of Public Health, University of Kentucky, Lexington, Kentucky, United States

²Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, United States

³COPD Foundation, Miami, Florida, United States

⁴Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States

Supplemental Figure 1. Participant-perceived disease management burden by disease group and sex (%).



BE- bronchiectasis; COPD-chronic obstructive pulmonary disease;
Note: BE group includes participants with self-reported bronchiectasis and/or NTM; COPD group includes participants with self-reported COPD with/without bronchiectasis and/or NTM;

Supplemental Table 1. Diagnosis-related resources, comorbidities, and symptoms reported by the participants by disease group and sex.

	COPD group^a 432 (68%)		BE group^b 200 (32%)	
	Women 295 (68%)	Men 137 (32%)	Women 173 (87%)	Men 27 (14%)
Resources and diagnosis information provided^c				
Educational Brochures	75 (25.4)	42 (30.7)	37 (21.4)	7 (25.9)
Consult Verbal info	76 (25.8)	48 (35.0)	59 (34.1)	9 (33.3)
Info line (phone (etc)	10 (3.4)	9 (6.6)	4 (2.3)	0 (0)
Clinical trial opp.	5 (1.7)	8 (5.8)	8 (4.6)	0 (0)
Patient support groups	19 (6.4)	12 (8.8)	15 (8.7)	1 (3.7)
Educational videos	2 (0.7)	5 (3.7)	6 (3.5)	0 (0)
Website(s)	12 (4.1)	15 (11.0)	24 (12.9)	1 (3.7)
No info or resources	130 (44.1)	50 (36.5)	79 (45.7)	12 (44.4)
Number of resources provided				
Mean (SD)	0.7 (0.9)	1.0 (1.2)	0.9 (1.3)	0.7 (0.7)
Comorbidities^c				
Alpha-1 Antitrypsin Deficiency	10 (3.4)	11 (8.0)	2 (1.2)	1 (3.7)
Congestive Heart Failure	29 (9.8)	21 (15.3)	2 (1.2)	1 (3.7)
Rheumatoid Arthritis	19 (6.4)	16 (11.7)	9 (5.2)	0 (0)
Coronary Artery Disease	31 (10.5)	18 (13.1)	8 (4.6)	4 (14.8)
Immunodeficiency	4 (1.4)	3 (2.2)	4 (2.3)	1 (3.7)
Osteoarthritis	95 (32.2)	17 (12.4)	50 (28.9)	2 (7.4)
Cystic Fibrosis	0 (0)	0 (0)	1 (0.6)	0 (0)
Kartagener Syndrome or Primary Ciliary Dyskinesia	1 (0.3)	0 (0)	2 (1.2)	0 (0)
Diabetes	27 (9.2)	16 (11.7)	7 (4.1)	2 (7.4)
Lung Cancer	15 (5.08)	7 (5.1)	0 (0)	0 (0)

	COPD group^a 432 (68%)		BE group^b 200 (32%)	
	Women 295 (68%)	Men 137 (32%)	Women 173 (87%)	Men 27 (14%)
Other	72 (24.4)	14 (10.2)	32 (18.1)	20 (22.2)
None / Missing	97 (32.9)	57 (41.6)	85 (49.1)	72 (55.6)
Number of comorbidities reported Mean (SD)	1.0 (1.0)	0.9 (0.9)	0.7 (0.8)	0.6 (0.8)
Symptoms^c				
Cough	188 (63.7)	92 (67.2)	138 (79.8)	24 (88.9)
Sputum	183 (62.0)	92 (67.2)	137 (79.2)	21 (77.8)
Chest pain	71 (24.07)	25 (18.5)	38 (22.0)	5 (18.5)
Repeated lung infections	84 (28.5)	45 (32.9)	72 (41.6)	12 (44.4)
Wheezing	146 (49.5)	68 (49.6)	60 (34.7)	10 (37.0)
Weight loss	67 (22.71)	15 (11.0)	43 (24.9)	8 (29.6)
Shortness of breath	266 (90.2)	123 (89.8)	99 (57.2)	17 (63.0)
Hemoptysis	13 (4.4)	6 (4.4)	41 (23.7)	5 (18.5)
Chills	32 (10.9)	12 (8.8)	40 (23.1)	2 (7.4)
Fever	17 (5.8)	5 (3.7)	17 (5.8)	2 (7.4)
Fatigue	214 (72.6)	92 (67.2)	120 (69.4)	17 (63.0)
No symptoms	4 (1.4)	2 (1.5)	2 (1.2)	0 (0)
Number of symptoms reported Mean (SD)	4.3 (2.2)	4.2 (2.2)	4.7 (2.5)	4.6 (2.3)

Note: BE- bronchiectasis; COPD-chronic obstructive pulmonary disease; ^aCOPD group includes participants with self-reported COPD with/without bronchiectasis and/or NTM; ^bBE group includes participants with self-reported bronchiectasis and/or NTM; ^cmultiple response options can be selected;

Supplemental Table 2. Associations between age, comorbidity count, and treatment burden in the overall cohort, stratified by sex

Analysis	Sex	Test statistic
Association between treatment burden and age using Spearman correlation	Men	$\rho=-0.23$
	Women	$\rho=-0.12$
Association between treatment burden and comorbidity count using Mann–Whitney U test	Men	$Z=2.19$
	Women	$Z=1.46$

Note: Treatment burden was assessed using a 5-point Likert scale; comorbidity count was dichotomized as fewer than 2 vs. 2 or more.